Objective: Nuclear depletion and mislocalization of RNA-binding proteins (RBPs) transactivation response DNA-binding protein of 43 kDa (TDP-43) and fused in sarcoma (FUS) are thought to contribute to the pathogenesis of a number of disorders, including amyotrophic lateral sclerosis (ALS). We recently found that TDP-43 as well as polypyrimidine tract binding protein (PTB) have decreased expression and mislocalization in oligodendrocytes in demyelinated lesions in an experimental mouse model of multiple sclerosis (MS) caused by Theiler's murine encephalomyelitis virus infection. Methods: The latter finding prompted us to investigate TDP-43, FUS, and PTB in the demyelinated lesions of MS and in in vitro cultured human brain-derived oligodendrocytes. Results: We found: i) mislocalized TDP-43 in oligodendrocytes in active lesions in some MS patients; ii) decreased PTB1 expression in oligodendrocytes in mixed active/inactive demyelinating lesions; iii) decreased nuclear expression of PTB2 in neurons in cortical demyelinating lesions; iv) nuclear depletion of TDP-43 in oligodendrocytes under metabolic stress induced by low glucose/low nutrient conditions compared to optimal culture conditions.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) characterized pathologically by sharply demarcated plaques of demyelination along with axonal injury and reactive astrocytosis. Clinically MS often runs a relapsing-remitting course that is reflected in different histopathologic patterns of demyelinating plaques, which are typically described as active, mixed active/inactive or "chronic" 1 . Progressive clinical disability is linked to demyelination in the white matter and cerebral cortex as well as cortical atrophy. The etiology and pathological mechanisms that drive white matter demyelination and neurodegeneration remain poorly understood.
Here we identify abnormalities in the expression and localization of RNA-binding proteins (RBPs) in MS lesions and in oligodendrocytes exposed in vitro to metabolic stress conditions. RBPs bind to double or single stranded RNA in cells and participate in the formation of ribonucleoprotein complexes (reviewed in 2 ). These proteins play a key role in RNA biology, such as splicing, polyadenylation, mRNA stabilization, mRNA localization, and translation. Most RBPs reside in the nucleus in order to carry out their function, and shuttle across the nuclear membrane in association with mRNAs. Decreased expression and mislocalization of RBPs, including trans-activation response (TAR) DNA-binding protein of 43 kDa (TDP-43) and fused in sarcoma (FUS), have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia 2 .
We recently investigated the expression and mislocalization of RBPs in infections with
Theiler's murine encephalomyelitis virus (TMEV), a member of the Cardiovirus genus of Picornaviridae 3 . Polypyrimidine tract binding protein (PTB) is known to have an abnormal nuclear localization in TMEV-infected cells as a result of interference of nucleocytoplasmic transport by a TMEV protein (reviewed in 4 ); the mislocalization has been hypothesized to play a role in neuronal dysfunction in TMEV-induced disease 5 . We questioned whether other RBPs were also abnormally distributed in TMEV infections, and might contribute to disease pathogenesis. We found that TDP-43 and FUS, in addition to PTB, were mislocalized in TMEV-infected neural cells, including oligodendrocytes, in demyelinating lesions. Since TMEV-induced immune-mediated demyelination serves as an experimental model of MS, we carried out the present investigation in order to determine whether the expression pattern and localization of these RBPs were also abnormal in MS. We focused on three RBPs -TDP-43, FUS, and PTB (which included paralogs PTB1 and PTB2)since they have been found to play an important role in TMEV infections and/or ALS.
In the present study, we found a number of examples of abnormal expression and mislocalization of RBPs in MS lesions and in in vitro cultured oligodendrocytes: i) mislocalization of TDP-43 in oligodendrocytes in active demyelinating lesions; ii) decreased expression of PTB1 in oligodendrocytes in mixed active/inactive demyelinating lesions; iii) decreased nuclear expression of PTB2 in neurons in cortical demyelinating lesions; iv) nuclear depletion of TDP-43 in cultured oligodendrocytes under metabolic stress conditions. These results suggest that altered expression of RBPs in demyelinating lesions of MS may disrupt key cellular processes, and thereby contribute to the pathogenesis of demyelination and neurodegeneration. A recent publication demonstrated that TDP-43 is important for oligodendrocyte survival and myelination 6 . In addition, PTB is known to be critically important for splicing repression and neuronal differentiation 7, 8 . The significance of these two RBPs to central nervous system function emphasizes the relevance of our results, and the potential importance of nucleocytoplasmic transport as a target for treatment.
Methods

Ethics
statement, Human Samples, Tissue preparation and immunohistochemistry/immunofluorescence (see Supplement)
Staging of demyelinating lesions
We classified MS plaques into three stages 1 based on the density of macrophages: i) active -lesions densely and diffusely infiltrated with macrophages, ii) mixed active/inactive -lesions with macrophages restricted to the periphery, and iii) inactive -lesions with no increase in macrophage numbers within the plaque. We classified cortical plaques into three subtypes: leukocortical (involving both white matter and cortex), intracortical, and subpial (superficial cortical).
Semi-quantitative analysis of RBPs mislocalization
Sections from blocks of cerebral cortex and white matter in all MS cases were stained with DAB or by fluorescence for RBPs that included TDP-43, PTB1, PTB2 and FUS. A semiquantitative assessment of RBP nuclear depletion and mislocalization or decreased expression in demyelinating lesions was performed by taking digital photographs with a CMOS camera at a resolution of 1636 × 1088 pixels with a ×20 (0.75 NA) objective. At least 3 different photographs of areas of one lesion that were more than 1 mm apart from each other in x and y directions were randomly taken for every demyelinating lesion. At least 100 neuronal or glial cells per each area were identified on the basis of cytological features 11 and scored based on the degree of mislocalization or decreased nuclear expression of RBPs compared to normal appearing white matter from the same case stained at the same time: -no or minimal; + mild (10-30 cells); ++ moderate (30-100 cells); +++ cases prominent (>100 cells (see Table e-1) .
In vitro studies
Oligodendrocytes were isolated and cultured from samples of 4 surgical resections (3 adults cases: 2 males, ages 57 and 38 and 1 female, age 51 and one pediatric case: male, age 7) that did not involve malignancies, as previously described 12, 13 . The tissue was from a site distant from visible pathology. The isolation technique involved initial dissociation of tissue using trypsin digestion followed by Pespan style="font-family:Arial"> gradient centrifugation to remove myelin. The total cell fraction was plated onto a non-coated flask that was kept overnight at 37°C to allow adhesion of the microglia fraction. Floating cells were then recovered (>90% were O4 + ) and plated into 12 well poly-L-lysine and extracellular matrix-coated chamber slides (30,000 cells per well) in defined medium (referred to as N1) consisting of Dulbecco's modified essential medium DMEM-F12
(Sigma-Aldrich) supplemented with N1 (Sigma-Aldrich), 0.01% bovine serum albumin,1% penicillin-streptomycin, B27 (Invitrogen), platelet-dreived growth factor with two A subunits (10 ng/ml), basic fibroblast growth factor (10 ng/ml), and triiodothyronine (2 nM) (Sigma-Aldrich). After 4 days, media in individuor with DMEM with 0.25g/L glucose (referred to as low glucose (LG). After an additional 2 or 6 days of N1 or LG treatment, cells were incubated with monoclonal O4 antibody and propidium iodide (PI) for 15 min at 37°C. Cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature and then stained with a secondary antibody directed against O4, goat anti-mouse IgM conjugated to AF-647 (SouthernBiotech). After permeabilization buffer with 0.1% Triton X-100, the cells were stained with polyclonal anti-TDP-43 antibody (Proteintech) for 1 hour at 37°C followed by goat anti-rabbit polyclonal antibody conjugated to AF-488 and Hoescht 33258 (Invitrogen) for 30 minutes. Cells were then examined using an epifluorescent microscope (Zeiss, Oberkochen, Germany) to determine the percent of O4 cells that were PI + cells and % of cells that showed predominantly nuclear versus cytoplasmic distribution of TDP-43.
Data were derived by blinded observers counting 75-100 cells per condition. Data between
LG and N1 conditions were compared using a paired t-test.
Statistical analysis
Data were analyzed using GraphPad Prism version 7.0a and are expressed as means ± standard error of the mean. Significance was assessed using Student's t test, and P values less than 0.05 were considered statistically significant.
Data availability statement
Any data not published within the article will be shared by request from any qualified investigator in anonymized form.
Results
TDP-43 in ALS
In ALS, TDP-43 is depleted from the nucleus in some motor neurons, and localized in aggregates in the cytoplasm (Fig 1A, arrows) , while other neurons and glial cells have TDP-43 in its normal location in the nucleus ( Fig 1A, B , arrowhead), At times phosphorylated TDP-43 (pTDP-43) is present in the cytoplasmic aggregates ( Fig 1C) Two other RBPs, PTB2 and FUS, maintain their normal nuclear localization in cells in the same region that have TDP-43 mislocalization ( Fig. 1D , F). PTB1 was not detected in motor neurons ( Fig. 1E ), since it is known to have a limited distribution in this cell type 14 . In contrast to these finding in ALS, a predominant nuclear localization of TDP-43 is present in neurons and oligodendrocytes in human control CNS tissue ( Fig. 1G, H) .
Altered localization and expression of RBPs in oligodendrocytes in white matter
plaques TDP-43 was mislocalized to the cytoplasm in glial cells in active demyelinating lesions from patients MS#3 and 13 to a moderate degree (Table e- again, macrophages were present in the periphery of this plaque. The decrease in expression was statistically significant compared to oligodendrocytes in the PPWM (P = 0.0003) ( Fig. 3K ). expression in the nuclei and did not differ from that in NAGM (Table e-1) .
Alteration of RBPs in cortical plaques
TDP-43 proteinopathy in in vitro cultured primary human oligodendrocytes
We cultured primary human oligodendrocytes in a low glucose medium in order to model metabolic stress conditions thought to occur in MS lesions 12, 13 . As shown in Fig. 5A , there is only a low level of cell death under N1 conditions at day 2 in culture. Levels modestly increase under LG conditions, as previously described 12, 13 . By day 6, however, there was a significant increase in cell death under LG conditions. 
Discussion
Abnormalities of expression and localization of RBPs have been described in a number of diseases, including ALS, Huntington's disease, and viral infections 2 . In the present study, we focused on TDP-43, FUS, and PTB because these RBPs have an important impact on RNA biology and also because their mislocalization is thought to influence the pathogenesis of ALS and TMEV infections.
TDP-43 is a ubiquitously expressed RBP that predominantly resides in the nucleus, but shuttles across the nuclear membrane in association with mRNAs 15 . A hallmark of almost all cases of ALS is disruption of nucleocytoplasmic trafficking with resultant nuclear depletion, cytoplasmic mislocalization, aggregation, cleavage, and phosphorylation of TDP-43 in neural cells [16] [17] [18] . The decreased expression and mislocalization or TDP-43 are thought to cause abnormalities of splicing and RNA metabolism as well as add to nucleocytoplasmic transport disruption, thereby contributing to ALS pathogenesis [19] [20] [21] [22] . It is likely that cytoplasmic mislocalization of other RBPs in addition to TDP-43 adds to the cellular dysfunction in ALS 23 .
In the present study, we demonstrate a number of abnormalities in expression and localization of RBPs in MS lesions and in in vitro cultured oligodendrocytes. We found that TDP-43 was mislocalized in oligodendrocytes in demyelinated lesions in MS, as was the case in TMEV infections. Of note, TDP-43 is known to bind to 100s of mRNAs, including mRNAs encoding PLP, myelin basic protein, myelin oligodendrocyte glycoprotein, and myelin-associated glycoprotein, and to play a key role in RNA metabolism and splicing 24 .
Importantly and relevant to our findings is a recent report that an experimental decrease in expression of TDP-43 in mature oligodendrocytes in mice leads to demyelination and RIPK1-mediated necroptosis of oligodendrocytes 6 ; of note, necroptosis has been reported to occur in MS as well as experimental models of MS 25 . A conclusion of that investigation was that the TDP-43 knockdown led to a reduction in myelin gene expression, and that TDP-43 is indispensable for oligodendrocyte survival and demyelination 6 . These findings suggest that nuclear depletion and mislocalization of TDP-43 in MS lesions would similarly lead to demyelination and, in some cases, death of oligodendrocytes.
We found a decrease in PTB1 in oligodendrocytes in mixed active/inactive demyelinating lesions, as well as a decrease in PTB2 in neurons in cortical plaques. PTB1 and PTB2 are paralogous RBPs that are encoded by related genes 7 . PTB1 is not expressed in mature neurons and muscle, while PTB2 is expressed in these cells and others. These RBPs function in regulating alternative splicing, and also play a role in translation, mRNA stability, and polyadenylation. The control of splicing is especially important in the CNS because of the myriad of mRNA isoforms that have key roles in development and function.
Splicing in oligodendrocytes and neurons in MS demyelinated regions is likely impacted by the nuclear depletion and cytoplasmic mislocalization of PTB. Importantly, PTB is involved in the differentiation of neural precursor cells 7, 8 . In this way, PTB2 nuclear depletion and cytoplasmic mislocalization in neurons of cortical plaques may contribute to neurodegeneration and the cognitive decline associated with MS.
In summary, we found that there is disruption of TDP-43 and PTB expression and localization that varies in different neural cell types in MS plaques. This variation may have resulted from differences in the protein composition of the nuclear pore complex in different cell types 26 The nucleocytoplasmic transport abnormalities in MS that we identified may have resulted from a number of possible causes. Probably most relevant are reports that inflammation can lead to mislocalization of proteins in neural cells. Correia et al. 27 found that mislocalization of TDP-43 occurred in: cultured microglia and astrocytes following exposure to lipopolysaccharide (LPS); motor neuron-like NSC-34 cells after treatment with tumor necrosis factor-alpha (TNFa); and motor neurons of mutant TDP-43 transgenic mice following LPS intraperitoneal injections. Kim et al. 28 reported that treating neuronal cultures with glutamate and TNFa led to mislocalization of HDAC1 with resultant axonal damage.
The latter investigators also detected abnormal cytoplasmic localization of HDAC1 in damaged axons in MS patients and in mice with cuprizone-induced demyelination. Salapa et al. 29 found that interferon-γ led to cytoplasmic mislocalization of heterogeneous ribonuclear protein (hnRNP) A1, an RBP. These investigators also reported that neurons in a region of an MS brain (in which no pathology was described) had nuclear depletion and cytoplasmic mislocalization of hnRNP A1, which was aggregated in stress granules.
Our in vitro culture conditions were selected to model metabolic stress conditions that are thought to occur in MS lesions 12, 13 . Antel and colleagues previously showed that these conditions were associated with an initial withdrawal of cell processes, modelling the dying-back of oligodendrocyte processes observed in MS lesions (as well as cuprizoneinduced demyelination 30 and TMEV-induced demyelination 31 . These changes were reversible if culture conditions were restored within a subsequent 48 hours. If continued past this time, however, significant cell death occurs by 6 days, as shown in Fig. 5A , with activation of an autophagy response. In the current study, we found TDP-43 nuclear depletion was increased under LG conditions after 2 days in culture, a time when cell death levels as detected by PI staining were low. Importantly, we specifically observed nuclear depletion in cells that were still PI negative, in addition to PI+ cells that also showed nuclear depletion of TDP-43. These results are consistent with in situ data showing nuclear depletion of TDP-43 in oligodendrocytes with intact oligodendrocyte cell bodies. Of note, TNFa also leads to dying back of cultured oligodendrocytes, although in this case it was observed in newborn rat-derived oligodendrocytes 12 . The combined in vitro and in situ results suggest that the TDP-43 nuclear depletion reflects a cellular stress response that could be mediated both by the metabolic conditions and inflammatory mediators of MS lesions. Of note, no difference in TDP-43 transcripts was found in a microarray data set derived from oligodendrocytes under N1 vs LG conditions for 2 days 12 , suggesting that any change in TDP-43 protein levels is a result of translational regulation, presumably from stress, such as from low glucose 32 or inflammatory factors, triggering the integrated stress response. Activation of the integrated stress response has been previously implicated in the pathogenesis of MS 33 .
Our results suggest that correcting the expression and localization of RBPs in MS may ameliorate disease. In addition, this direction may lead to normal localization of key transcription factors and proteins that are required for efficient myelination and remyelination in oligodendrocytes and oligodendrocyte precursor cells [34] [35] [36] [37] . Importantly, nuclear export inhibitors have been found to attenuate myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis (as well as kainic acidinduced axonal damage) by limiting areas of myelin damage, preserving myelinated and unmyelinated axon integrity, and decreasing inflammation 38 . Nuclear export inhibitors have also been found to attenuate disease and to be neuroprotective in experimental models of ALS 39 , including a mutant TDP-43 mouse model 19 , and Huntington's disease 40 (which, like ALS, has abnormalities of nucleocytoplasmic transport). Furthermore, nucleocytoplasmic transport is being targeted in patients with cancer in addition to neurological diseasesand a clinical trial with a nuclear export inhibitor is in progress in ALS.
Altered nucleocytoplasmic transport leading to abnormal expression and mislocalization of
RBPs and other macromolecules may not only contribute to the demyelination and neurodegeneration in MS, but also underlie a number of other disease states, both infectious as well as non-infectious. The availability of drugs that target nucleocytoplasmic transport may provide new and novel treatment possibilities for these disorders. 
